Cara Community Biotechs: Vaxart

Vaxart Inc. (NASDAQ: VXRT) reviewed 10-13-2020

Market Cap: 737.4 Million (USD)               Share Price: $7.67 (USD)

Shares outstanding: 96,140,166 at 30 Jun 2020

Cash & cash equivalents: $ 44.4 M (USD) at 30 Jun 2020

Debt:     Nil

Insiders: Low, 1.2%          Institutional: 36 hold ~37% of float

Website: vaxart.com

Investor Presentations:  https://investors.vaxart.com/static-files/64808110-9390-4735-8076-392f35605b82

CEO: Andrei Floroiu         HQs: Boston, Mass, USA

The company develops vaccines that can be delivered via tablet form versus traditional injections

R&D pipeline includes four prophylactic vaccines in addition to seeking licenses, to address these viruses:

  • COVID-19 – on 13 Oct 2020 announced the 1st dosing of a human subject in Phase 1 Trial (oral tablet vaccine)
  • Influenza – Phase 1
  • Novovirus – Phase 1
  • Respiratory Syncytial Virus (RSV) – Pre-clinical
  • Also developing human papillomavirus (HPV) vaccine

Unprofitable: Q2 2020 Revenues of $523,000 (USD) vs operating expenses of $9 Million (USD)

Bottom line:

  • We have a position
  • Their oral vaccine delivery system will be favored over needles that inject fluids into your body
  • In mass production, their technology will be far less costly than the competition
  • Presently, this technology is in phase 1 clinical trial whereas the competition is mostly in phases 2 & 3. But if Vaxaer is successful, they could receive ~$400 million in OWS funding

Like to give your opinion? Join our Community Discussion